报价延迟最少15分钟:2025/11/16 04:44 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.5 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-12.12/-3.02
|
|
企业价值
11.51M
|
| 资产负债 |
|
每股账面净值
2.52
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/11/16 04:44 EST
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism. |
